华东医药(000963) - 2017 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 20.28% to CNY 447,718,499.59 for the current period[8]. - Operating revenue for the current period reached CNY 7,359,928,723.14, reflecting a growth of 10.24% year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 448,659,423.83, up 20.95% from the same period last year[8]. - Basic earnings per share decreased by 39.77% to CNY 0.4606 due to an increase in share capital[8][9]. - The weighted average return on equity was 6.19%, an increase of 0.22% compared to the previous year[8]. Asset Changes - Total assets increased by 9.18% to CNY 15,784,212,697.28 compared to the end of the previous year[8]. - Cash and cash equivalents decreased by 35.23% to ¥1,723,721,634.34 due to significant net outflows from investment activities and loan repayments[20]. - Accounts receivable increased by 42.25% to ¥6,353,135,322.69, primarily due to expanded sales scale[20]. - Other receivables surged by 255.49% to ¥106,000,203.03, mainly due to an increase in temporary payments[20]. - Construction in progress rose by 224.78% to ¥260,071,062.51, attributed to ongoing projects at the company's industrial subsidiaries[20]. - Goodwill increased by 120.24% to ¥31,398,193.89, resulting from the acquisition of new subsidiaries[20]. Cash Flow - Cash flow from operating activities showed a significant decline of 72.77%, totaling CNY 126,280,983.94 year-to-date[8]. - Cash flow from operating activities decreased by 72.77% to ¥126,280,983.94, primarily due to reduced bill discounts and increased cash payments for taxes and operating expenses[21]. - Other income increased to ¥30,163,069.73, mainly from government subsidies related to demolition compensation[21]. - Investment cash payments increased by 84.10% to ¥220,922.84, primarily due to higher equity acquisition payments[21]. Shareholder Information - The total number of shareholders at the end of the reporting period was 22,660[14]. - The largest shareholder, China Yuanda Group, holds 41.77% of the shares, amounting to 406,076,754 shares[14]. - The company did not engage in any repurchase transactions during the reporting period[15]. Expenses - Management expenses rose by 32.94% to ¥676,320,157.21, mainly due to increased R&D expenses at industrial subsidiaries[21]. - Financial expenses decreased by 50.33% to ¥38,436,371.85, due to a reduction in interest-bearing liabilities[21].